B. Riley Raises Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at B. Riley lifted their Q2 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Wednesday, July 16th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of ($0.01) for the quarter, up from their prior estimate of ($0.04). B. Riley currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' FY2025 earnings at $0.52 EPS, FY2028 earnings at $2.25 EPS and FY2029 earnings at $2.51 EPS.

A number of other research analysts have also issued reports on ETON. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON traded up $0.19 during midday trading on Monday, reaching $14.59. 545,427 shares of the company's stock were exchanged, compared to its average volume of 368,094. The firm has a market capitalization of $391.27 million, a PE ratio of -81.06 and a beta of 1.18. The company's 50 day simple moving average is $16.14 and its two-hundred day simple moving average is $15.33. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97. Eton Pharmaceuticals has a 12 month low of $3.25 and a 12 month high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million.

Insider Activity at Eton Pharmaceuticals

In related news, insider David Krempa sold 16,977 shares of the firm's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84. Following the completion of the transaction, the insider directly owned 629,669 shares in the company, valued at $9,394,661.48. This trade represents a 2.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 34,000 shares of company stock valued at $504,318 over the last 90 days. 16.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Mink Brook Asset Management LLC bought a new stake in Eton Pharmaceuticals in the 4th quarter worth about $6,071,000. Cannell Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth about $5,079,000. Millennium Management LLC grew its position in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after buying an additional 217,042 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Eton Pharmaceuticals by 61.9% in the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company's stock valued at $5,219,000 after purchasing an additional 153,923 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock valued at $14,898,000 after buying an additional 119,750 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.